Search Within

Robert Motzer

Formats
  1. Journal Article (609)
  2. Meeting Abstract (578)
  3. Book Section (20)
  4. Review (13)
  5. Conference Paper (6)
  6. Correspondence (6)
  7. Guidelines (5)
  8. Research Letter (5)
  9. Editorial (3)
  10. Book Whole (2)
Groups
  1. Department of Medicine (1247)
  2. Genitourinary Oncology Service (1247)
  3. Solid Tumor Oncology Division (1247)
  4. Surgery (290)
  5. Urology (281)
  6. Survivorship Research (253)

More Groups

People
  1. George Bosl (182)
  2. Martin Voss (178)
  3. Darren Feldman (158)
  4. Dean Bajorin (128)
  5. Paul Russo (119)
  6. Joel Sheinfeld (110)

More People

Years
  1. 2025 (30)
  2. 2024 (49)
  3. 2023 (47)
  4. 2022 (64)
  5. 2021 (65)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (448)
  2. Annals of Oncology (81)
  3. BJU International (40)
  4. Cancer (35)
  5. European Journal of Cancer (34)
  6. Clinical Cancer Research (33)

More Publications

Publishers
  1. American Society of Clinical Oncology (451)
  2. Elsevier Science, Inc. (111)
  3. Oxford University Press (111)
  4. Elsevier Inc. (89)
  5. Wiley Blackwell (86)
  6. American Association for Cancer Research (58)

More Publishers

Results (1247)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms
    Meeting Abstract

    Hutson, T. E.; Choueiri, T. K.; Motzer, R. J.; Rha, S. Y.; Alyasova, A.; Merchan, J. R.; Gurney, H.; Peer, A.; Takagi, T.; Porta, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Porta, C.; Alekseev, B.; Rha, S. Y.; Choueiri, T. K.; Mendez-Vidal, M. J.; Hong, S. H.; Kapoor, A.; Goh, J. C.; Eto, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC)
    Meeting Abstract

    Shah, A. Y.; Motzer, R. J.; Apolo, A. B.; Powles, T.; Escudier, B.; Zhang, J.; Scheffold, C.; Karumanchi, S.; Nguyen, L. T.; Choueiri, T. K.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101
    Meeting Abstract

    Haanen, J. B. A. G.; Larkin, J.; Choueiri, T. K.; Albiges, L.; Rini, B. I.; Atkins, M. B.; Schmidinger, M.; Penkov, K.; Thomaidou, D.; Wang, J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial
    Meeting Abstract

    Lee, C. H.; Shah, A. Y.; Hsieh, J. J.; Rao, A.; Pinto, A.; Bilen, M. A.; Cohn, A. L.; DiSimone, C.; Shaffer, D. R.; Sarrió, R. G.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N+C) versus sunitinib (SUN) in treatment-naïve, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data
    Meeting Abstract

    Cella, D.; Motzer, R. J.; May, J.; Wallace, J.; Marteau, F.; Kwon, Y.; Rusibamayila, N.; Botteman, M.; Ejzykowicz, F.; Choueiri, T. K.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Plimack, E. R.; Hammers, H. J.; Choueiri, T. K.; Rini, B. I.; Motzer, R. J.; Suttner, L.; Perini, R. F.; Rogerio, J. W.; Albiges, L.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Long-term trend of quality-adjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the first-line treatment of advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Choueiri, T. K.; May, J.; Kwon, Y.; Rusibamayila, N.; Botteman, M.; Hamilton, M.; Ejzykowicz, F.; Cella, D.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Immunity to childhood vaccines following high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for germ cell tumors (GCT) with comparison to Hodgkin lymphoma (HL)
    Meeting Abstract

    Feldman, D. R.; Lewis, A. R.; Knezevic, A.; Ali, D.; Bromberg, M.; Aronson, J.; Funt, S. A.; McHugh, D. J.; Motzer, R. J.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Reznik, E.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Tassone, D.; Dadoun, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save